| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a9bf8f8527cfdd7e1b25a4c8f3cca470 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1272
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6913 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 |
| filingDate |
2017-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a5e34b0d175f069847201d7fbf4f29b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ac830b4f2da5e7038af89bf70e2deac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3099e80d45984a27086b88fa739b4557
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e71196d83bb9c6f0636dedac19519cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9423173775c2604a68c44a569ee0605 |
| publicationDate |
2018-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20180121904-A |
| titleOfInvention |
Ephrin Receptor A2 (EphA2) -donated docetaxel-producing nano-liposome composition |
| abstract |
EphA2-targeted immunoliposomes for docetaxel delivery are useful in the treatment of certain types of cancer. Immunoliposomes can contain an EphA2 targeting moiety (e.g., scFv) and encapsulate the docetaxel prodrug in stable salt form in liposomes having an average size of about 100 nm. Novel docetaxel prodrugs suitable for loading into nanoliposomes (including immunoliposomes) are provided, along with new and other useful EphA2 targeting moieties for the preparation of EphA2-targeted doxorubicin-producing immunosuperomycin therapy. Pharmaceutical compositions comprising nanoliposomes encapsulating at least one docetaxel prodrug drug, and / or immunoliposomes or nanoparticles comprising an EphA2 binding moiety and encapsulating at least one docetaxel prodrug may be prepared. The pharmaceutical composition is useful for administration to a patient for cancer treatment. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20220159289-A |
| priorityDate |
2016-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |